Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2021-06-05 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
FORM S-8-Registration Statement
Report Publication Announcement Classification · 1% confidence The document is a regulatory filing notification from ENLIVEX THERAPEUTICS LTD, reported via MAGNA to the Israel Securities Authority and the Tel Aviv Stock Exchange on 04/06/2021. The key indicator is the line: "Attached hereto is a report on *S-8* *S8_04062021_isa.pdf*". This structure—a brief announcement stating that a specific report (in this case, referencing an S-8 filing type, which is typically related to employee stock plans but here is being filed under Israeli regulations) is attached or published—fits the definition of a Report Publication Announcement (RPA). Given the very short length (1829 chars) and the explicit mention of attaching another document, it is not the full report itself (like 10-K or IR). Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2021-06-05 English
Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which corresponds to a Form 6-K filing. Form 6-K filings are generally used by foreign private issuers to report material information to the SEC, often mirroring the function of a current report (8-K) in the US system. The content is a press release announcing the issuance of a Canadian Patent, which is material information. Since Form 6-K is not explicitly listed in the provided codes, and this document is a formal regulatory filing containing material, non-periodic information (patent grant announcement), it best fits the general regulatory filing category. The closest fit among the provided options for a non-standard, material regulatory submission that isn't a core periodic report (10-K, IR, MRQ) is RNS (Regulatory Filings), which serves as a general regulatory announcement fallback.
2021-06-01 English
Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
Report Publication Announcement Classification · 1% confidence The document is very short (1767 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K01062021_isa.pdf*". This structure—a brief announcement pointing to an attached or linked official filing (in this case, a Form 6-K, which is a report filed by foreign private issuers)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. Since RPA is available, it takes precedence over the general fallback RNS.
2021-06-01 English
Form 6-K-FIRST QUARTER 2021 RESULTS
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three-month period ended March 31, 2021. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (quarterly) that contains actual financial statements is classified as an Interim / Quarterly Report (IR). Q1 2021
2021-05-29 English
Form 6-K-FIRST QUARTER 2021 RESULTS
Report Publication Announcement Classification · 1% confidence The document is very short (1767 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k28052021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report for foreign private issuers often filed with the SEC, but here it is being reported to the Israel Securities Authority and TASE). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcement, RPA is the most appropriate specific category, although RNS is a close fallback.
2021-05-29 English
Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K" filed with the SEC by a Foreign Private Issuer. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's stock exchange or make public in its home country, or information that it has made or will make public pursuant to the laws of its home country. The content is a press release announcing the receipt of a non-dilutive grant from the Israel Innovation Authority. While the content relates to financial/operational updates, the filing structure itself (Form 6-K) is a general reporting mechanism for foreign private issuers. Among the provided codes, 'RNS' (Regulatory Filings) is the most appropriate general category for SEC filings that are not 10-K, ER, or IR, especially when the core document is a submission wrapper (Form 6-K) for a press release. Since the document is substantial (6991 chars) and contains the full press release, it is not just a simple announcement of a report (RPA). Given the options, RNS serves as the best fit for a standard, non-core SEC filing like a 6-K.
2021-05-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.